Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS1440 +/- ATRA in r/r AML
NCT04282668Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Mar 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAS1440 in acute myeloid leukemia (AML) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Treatment-Emergent Adverse Events. Started Mar 2020; status: terminated.
02
Drugs
TAS1440
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04282668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282668.